Proove Biosciences has presented at the Pain Society of the Carolinas Annual Meeting

Share Article

Bilikis Akindale, MD MMCi, of Proove Biosciences presented a study of Genetics and Oxycodone Response to determine the Influence of Variations in ANKK1 and DBH in Individual Response to Oxycodone Medication (Among Patients with Spondylosis & Allied Disorders).

This new information could help guide future prescription decisions to avoid misuse and abuse.

Proove Biosciences, a commercial and research leader in Personalized Medicine, presented research conducted through their genetic testing for drug responses.

The Pain Society of the Carolinas Annual Meeting focuses on the rapidly expanding field of pain management.

Genetic factors are believed to account for 20-95% of observed variation in a patient’s response to prescription drugs. However, this is not typically explored before the commencement of a prescription regime, as the role of unique genes is poorly understood. Overdoses of opioids such as Oxycodone and Hydrocodone are the second leading cause of accidental death in the United States. The misuse and abuse of opioid medication is seen as a major part of the Public Health Crisis of Prescription Drug Abuse.

In this study, conducted with data from a population of 1580 pain patients using oxycodone only, it is suggested that ANKK1 and DBH may play an active role in the observed differences in the therapeutic response to the use of Oxycodone. Also suggested is that response to opioid medications may be more influenced by the genes of the mesolimbic neural circuitry than previously thought.

“This new information could help guide future prescription decisions to avoid misuse and abuse.", says Bilikis.

About Proove Biosciences

Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We envision a future where physicians will know how patients are likely to respond to medications before writing a prescription. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Keira Dazi
Proove Biosciences
+1 855-776-6832 Ext: 1594
Email >
@proovebio
Follow >
Proove Biosciences, Inc.
since: 01/2012
Like >